GWS
RARE icon

Glassman Wealth Services’s Ultragenyx Pharmaceutical RARE Stock Holding History

Glassman Wealth Services’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-18
Closed -$1K – 1922
2022
Q2 		$1K Buy
+18
New +$1.11K ﹤0.01% 1502
2021
Q2 		– Sell
-1
Closed – – 1603
2021
Q1 		$0 Buy
+1
New +$136 ﹤0.01% 1590
2019
Q4 		– Sell
-6
Closed – – 1423
2019
Q3 		$0 Hold
6
– – ﹤0.01% 1314
2019
Q2 		$0 Hold
6
– – ﹤0.01% 1313
2019
Q1 		$0 Hold
6
– – ﹤0.01% 1180
2018
Q4 		$0 Hold
6
– – ﹤0.01% 948
2018
Q3 		$0 Hold
6
– – ﹤0.01% 938
2018
Q2 		$0 Hold
6
– – ﹤0.01% 925
2018
Q1 		$0 Buy
+6
New +$302 ﹤0.01% 883

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Glassman Wealth Services's RARE Position: Q3 2022 in Review

Glassman Wealth Services sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2022, closing a stake of 18 shares — an estimated $1K sold.

Glassman Wealth Services first reported a position in RARE in Q1 2018 and held it in 9 quarters. The position peaked at $1K in Q2 2022. 232 funds tracked by Wall St. Rank hold RARE as of Q3 2022.

  • Glassman Wealth Services reported no remaining Ultragenyx Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • Glassman Wealth Services sold 18 Ultragenyx Pharmaceutical shares in Q3 2022, an estimated $1K.
  • Glassman Wealth Services first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and held it in 9 quarters.
  • Glassman Wealth Services's Ultragenyx Pharmaceutical position peaked at $1K in Q2 2022.
  • 232 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2022.

Based on Glassman Wealth Services's 13F filing for Q3 2022, filed 9 Nov 2022.